Proscia, a Philadelphia, PA-based software company improving pathology’s transition to digital and AI, raised $50M in funding.
The round, which brought the total amount to $130M, was led by Insight Partners along with AI Capital Partners (Alpha Intelligence Capital’s US fund) and Triangle Peak Partners. Other investors included Avenue Venture Opportunities Fund, Emerald Development Managers, GPG Healthcare, Fusion Fund, Interwoven Ventures, and Razor’s Edge.
The company intends to use the funds to grow its customer footprint and advance Concentriq, with focus on extending the platform’s core AI capabilities.
Led by CEO David West, Proscia is a software company accelerating pathology’s transition to a digital, data-driven discipline and enabling AI to advance precision medicine. Its Concentriq enterprise pathology platform, precision medicine AI portfolio, and real-world data accelerate the development and use of novel therapies and diagnostics to drive the fight against most challenging diseases, like cancer.
Pharmaceutical companies and a global network of diagnostic laboratories use its solutions each day. The company has FDA 510(k) clearance and CE-IVDR certification for its diagnostic software.
FinSMEs
19/03/2025